Pharmacie Centrale DE Guinee, Pharmaceutical Import Profile — Guinea (DGFT 2022–2026)

Name: Pharmacie Centrale DE Guinee, Pharmaceutical Import Records from India — 5 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharmacie Centrale DE Guinee, — Pharmaceutical Importer Profile (2026) | 5 Products, $1.1M Trade | TransData Nexus

Pharmacie Centrale DE Guinee,

Pharmaceutical Importer · Guinea · Combination Drugs Focus · $1.1M Total Trade · DGFT Verified

Pharmacie Centrale DE Guinee, is a pharmaceutical importer based in Guinea with a total trade value of $1.1M across 5 products in 3 therapeutic categories. Based on 41 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Pharmacie Centrale DE Guinee, sources from 2 verified Indian suppliers, with Bharat Parenterals Limited accounting for 100.0% of imports.

Pharmacie Centrale DE Guinee, — Import Portfolio & Supplier Network

Pharmacie Centrale DE Guinee, import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Pharmacie Centrale DE Guinee,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bharat Parenterals Limited	$870.8K	29	100.0%
Mylan Laboratories Limited	$365	2	0.0%

Pharmacie Centrale DE Guinee, sources from 2 verified Indian suppliers across .

What Formulations Does Pharmacie Centrale DE Guinee, Import?

Formulation	Value	Ships
Amoxycillin for oral suspension BP 250MG	$84.9K	3
Paracetamol oral suspension BP. unit	$73.7K	2
Acetylsalicylic acid ( aspirin ) 300MG	$70.3K	3
Povidone iodine topical solution USP.	$67.8K	2
Erythromycin stearate tablet BP 500MG.	$50.0K	1
Erythromycin stearate tablet BP 500MG	$50.0K	1
Griseofulvin tablets 500MG. (Each	$50.0K	1
Misoprostol tablets 200mcg. ( unit	$50.0K	1
Paracetamol oral suspension BP 125MG/5ML	$49.1K	3
Erythromycin stearate tablet BP	$47.3K	1
Metronidazole suspension 200MG/5ML.	$45.8K	1
Acetylsalicylic acid (aspirin) 300MG TAB	$45.3K	1
Metronidazole suspension 200MG/5ML	$27.7K	1
Amoxicillin for oral suspension BP 250MG	$24.5K	1
Co-trimoxazole for oral suspension.	$24.3K	1

Pharmacie Centrale DE Guinee, imports 23 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Mebendazole	Antimalarial & Antiparasitic	$257.8K	18	1.9%	8
2	Trimethoprim	Advanced Antibiotics	$250.0K	5	0.9%	14
3	Salicylic	Combination Drugs	$212.3K	9	1.3%	14
4	Acetylsalicylic	Combination Drugs	$207.9K	6	2.6%	8
5	Sulfamethoxazole	Advanced Antibiotics	$150.0K	3	0.8%	14

Pharmacie Centrale DE Guinee, imports 5 pharmaceutical products across 3 categories into Guinea totaling $1.1M.

Pharmacie Centrale DE Guinee, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Pharmacie Centrale de Guinée (PCG) is a public enterprise established on December 17, 1992, by decree number D/92/133/PRG/SGG, following the dissolution of "Pharma-Guinée." Operating under the Ministry of Health, PCG's primary mission is to ensure the consistent and regular supply of quality health products to both public and private healthcare facilities across Guinea. This includes the procurement, storage, and distribution of essential medicines and medical supplies, aiming to enhance accessibility and affordability for the Guinean population.

Headquartered in Conakry, Guinea's capital, PCG functions as the central procurement agency for the government, playing a pivotal role in the nation's pharmaceutical distribution network. The organization is governed by a Board of Directors and managed by a General Directorate, overseeing various departments dedicated to its operational functions. In recent years, PCG has undertaken significant reforms to strengthen its capacity, including the inauguration of a new storage warehouse in November 2023, aimed at bolstering its logistical and operational capabilities.

2Distribution Network

PCG's distribution network is centered in Conakry, with its main warehouse located in the Dixinn district. This strategic location facilitates efficient storage and distribution of pharmaceutical products throughout Guinea. The organization has also expanded its logistical infrastructure by inaugurating a new storage facility in November 2023, enhancing its capacity to manage and distribute medical supplies effectively.

3Industry Role

As the central procurement agency for the Guinean government, PCG serves as the primary wholesaler of pharmaceutical products in the country. It is responsible for sourcing, storing, and distributing medicines and medical supplies to both public and private healthcare institutions, ensuring a steady supply of quality health products nationwide. This central role positions PCG as a critical entity in Guinea's pharmaceutical supply chain, directly impacting the availability and accessibility of essential medicines for the population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Pharmacie Centrale DE Guinee,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

PCG's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, PCG imported finished pharmaceutical formulations totaling $1.1 million USD from India, comprising 41 shipments across five products in three therapeutic categories. The top five products imported include Mebendazole ($258K), Trimethoprim ($250K), Salicylic ($212K), Acetylsalicylic ($208K), and Sulfamethoxazole ($150K). This concentration indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities, ensuring a consistent supply of quality medicines.

The relationship stability with Indian suppliers appears strong, as evidenced by the consistent volume of imports over the years. The primary supplier, Bharat Parenterals Limited, accounted for $871K across 29 shipments, while Mylan Laboratories Limited contributed $365K through two shipments. This sustained engagement suggests a reliable and ongoing partnership, reducing the risks associated with supplier dependency.

2Supply Chain Resilience

PCG's supply chain resilience is bolstered by its diversified sourcing strategy, primarily from India, which is known for its stringent regulatory standards and quality manufacturing practices. The consistent importation of finished pharmaceutical formulations from India indicates a stable and reliable supply chain. However, the limited number of suppliers—two verified Indian suppliers—may pose risks in terms of supply chain flexibility and responsiveness to market changes. To enhance resilience, PCG could consider diversifying its supplier base and exploring alternative sourcing options.

Importing Pharmaceuticals into Guinea — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Guinea

1Regulatory Authority & Framework

In Guinea, the regulatory authority overseeing pharmaceutical imports is the Ministry of Health, which is responsible for ensuring the safety, efficacy, and quality of medical products entering the country. Key legislation governing pharmaceutical imports includes the Law L/2018/024/AN of June 20, 2018, which pertains to medicines, health products, and the practice of pharmacy. This law outlines the regulatory framework for the importation, distribution, and use of pharmaceutical products in Guinea, ensuring compliance with international standards and safeguarding public health.

2Import Licensing & GMP

Import licensing requirements in Guinea mandate that all pharmaceutical products undergo a registration process with the Ministry of Health before being imported and distributed. This process ensures that imported medicines meet the country's safety and efficacy standards. Guinea recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, including the World Health Organization (WHO) and the European Union (EU). Pharmaceutical companies seeking to supply PCG must ensure their products are manufactured in facilities holding valid GMP certifications from these recognized authorities.

Quality & Labeling

Pharmacie Centrale DE Guinee, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

PCG's focus on importing combination drugs, advanced antibiotics, and antimalarial and antiparasitic medications aligns with the prevalent health challenges in Guinea. Combination drugs are essential for treating complex infections, advanced antibiotics are crucial for combating resistant strains, and antimalarial and antiparasitic drugs are vital due to the high incidence of these diseases in the region. The market demand for these products is driven by the need to address public health concerns effectively and improve patient outcomes.

2Sourcing Profile

PCG's sourcing strategy emphasizes the procurement of generic drugs, particularly finished pharmaceutical formulations, to ensure affordability and accessibility. The preference for formulations that address a broad spectrum of diseases reflects a comprehensive approach to healthcare provision. India's established pharmaceutical industry, with its capacity for large-scale production and adherence to international quality standards, makes it a suitable partner for PCG's procurement needs.

3Market Positioning

PCG serves a diverse segment of the Guinean market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. By supplying a wide range of pharmaceutical products, it ensures that various healthcare providers have access to essential medicines, thereby supporting the overall healthcare infrastructure in Guinea.

Seller's Guide — How to Become a Supplier to Pharmacie Centrale DE Guinee,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with PCG, especially those offering products that complement the existing portfolio or address unmet needs in the Guinean market. Gaps in PCG's current sourcing include a limited number of suppliers and a narrow product range in certain therapeutic areas. Indian exporters can explore these opportunities by ensuring compliance with Guinea's regulatory requirements and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters aiming to supply PCG must ensure their products are manufactured in facilities holding valid GMP certifications from recognized authorities such as the WHO or EU. Additionally, compliance with Guinea's import licensing requirements, including product registration with the Ministry of Health, is mandatory. Products must meet Guinea's quality standards, including batch testing and stability requirements, and labeling must be in French, adhering to the country's regulations.

3How to Approach

Frequently Asked Questions — Pharmacie Centrale DE Guinee,

What products does Pharmacie Centrale DE Guinee, import from India?

Pharmacie Centrale DE Guinee, imports 5 pharmaceutical products across 3 categories. Top imports: Mebendazole ($257.8K), Trimethoprim ($250.0K), Salicylic ($212.3K), Acetylsalicylic ($207.9K), Sulfamethoxazole ($150.0K).

Who supplies pharmaceuticals to Pharmacie Centrale DE Guinee, from India?

Pharmacie Centrale DE Guinee, sources from 2 verified Indian suppliers. The primary supplier is Bharat Parenterals Limited (100.0% of imports, $870.8K).

What is Pharmacie Centrale DE Guinee,'s total pharmaceutical import value?

Pharmacie Centrale DE Guinee,'s total pharmaceutical import value from India is $1.1M, based on 41 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Pharmacie Centrale DE Guinee, focus on?

Pharmacie Centrale DE Guinee, imports across 3 categories. The largest: Combination Drugs (39.0%), Advanced Antibiotics (37.1%), Antimalarial & Antiparasitic (23.9%).

Get Full Pharmacie Centrale DE Guinee, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.